TI
NAVB

tru Independence’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

tru Independence’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed – – 956
2020
Q2 		$0 Hold
100
– – ﹤0.01% 954
2020
Q1 		$0 Hold
100
– – ﹤0.01% 960
2019
Q4 		$0 Buy
+100
New +$86 ﹤0.01% 958

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

tru Independence's NAVB Position: Q3 2020 in Review

tru Independence sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2020, closing a stake of 100 shares.

tru Independence first reported a position in NAVB in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q2 2020. 38 funds tracked by Wall St. Rank hold NAVB as of Q3 2020.

  • tru Independence reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 100 Navidea Biopharmaceuticals Inc. shares in Q3 2020.
  • tru Independence first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2019 and held it in 3 quarters.
  • tru Independence's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.